|
Corporate Presentation |
|
Analyst & Investor Day - June 2018 |
|
Treatment Efficacy and Safety of Seladelpar, a Selective Peroxisome Proliferator-Activated Receptor Delta agonist, in Primary Biliary Cholangitis Patients: 12- and 26-Week Analyses of an Ongoing, International, Randomized, Dose Ranging Phase 2 Study |
|
Seladelpar’s Mechanism of Action as a Potential Treatment for Primary Biliary Cholangitis and Non-Alcoholic Steatohepatitis |
|
Pharmacokinetics and Pharmacodynamics of Seladelpar, a Potent and Selective PPAR- Agonist, in Patients with Primary Biliary Cholangitis |
